ArticleHemaSphere2025

The impact of reduced dosing frequency of elranatamab on patient-reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-3.

Nizar J Bahlis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.